Analysts’ upgrades for Tuesday, July 11th:

Advanced Accelerator Applications (NASDAQ:AAAP) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They currently have $44.00 target price on the stock. According to Zacks, “Advanced Accelerator Applications S.A. is a radiopharmaceutical company. The company, develops, produces and commercializes molecular nuclear medicine diagnostic and therapeutic products. Its products in clinical development include Lutathera, Somakit and Annexin V-128. The company’s commercial products include Gluscan /Gluscan 500/Barnascan(R), IASOflu(R), IASOdopa(R), IASOcholine(R), MIBITEC/Adamibi and Leukokit(R). It operates primarily in France, Italy, the United Kingdom, Spain, Portugal, Israel, Switzerland, Germany and Canada. Advanced Accelerator Applications S.A. is headquartered in Saint Genis Pouilly, France. “

Aceto Corporation (NASDAQ:ACET) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Aceto Corporation markets, sells and distributes finished dosage form generics, nutraceutical products, pharmaceutical intermediates and active ingredients, agricultural protection products and specialty chemicals. The company’s operating segment consists of Human Health, Pharmaceutical Ingredients and Performance Chemicals. Human Health segment supplies raw materials used in the production of nutritional and packaged dietary supplements. It markets and distributes its generic prescription and over the counter pharmaceutical products. Pharmaceutical Ingredients segment offers active pharmaceutical ingredients and pharmaceutical intermediates. Performance Chemicals segment provides specialty chemicals. It serves chemical, agricultural, human health and pharmaceutical industries. The company operates primarily in United States, Europe, and Asia. Aceto Corporation and is headquartered in Port Washington, New York. “

AEterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “AEterna Zentaris Inc. is a biopharmaceutical company focused on endocrine therapy and oncology. Its lead endocrinology program is a Phase 3 trial in benign prostatic hyperplasia (BPH) with cetrorelix, an LHRH antagonist already marketed for in vitro fertilization under the brand name Cetrotide. The lead oncology program is a Phase 2 trial in endometrial and ovarian cancer with AEZS-108, a targeted cytotoxic peptide conjugate. Other lead compounds include ozarelix for BPH and prostate cancer as well as perifosine for multiple cancers. “

Aspen Insurance Holdings Limited (NYSE:AHL) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Aspen Insurance Holdings is a Bermudian holding company that provides property and casualty reinsurance in the global market, property and liability insurance principally in the United Kingdom and surplus lines insurance in the United States. Aspen’s operations are conducted through its wholly-owned subsidiaries located in London, Bermuda and the United States: Aspen Insurance UK Limited, Aspen Insurance Limited and Aspen Specialty Insurance Company. “

Antero Resources Corporation (NYSE:AR) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $24.00 price target on the stock. According to Zacks, “Antero Resources Corporation is an independent oil and natural gas company. It is primarily engaged in the exploitation, development and acquisition of unconventional oil and liquids-rich natural gas properties primarily located in the Appalachian Basin in West Virginia, Ohio and Pennsylvania. Antero Resources Corporation is headquartered in Denver, Colorado. “

American Renal Associates Holdings (NYSE:ARA) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They currently have $20.00 price target on the stock. According to Zacks, “American Renal Associates Holdings, Inc. is a provider of dialysis services primarily in the United States. It also offers outpatient and inpatient dialysis treatments for patients suffering from chronic kidney failure. American Renal Associates Holdings, Inc. is based in Beverly, Massachusetts. “

Aradigm Corporation (NASDAQ:ARDM) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Aradigm Corp. is a leading developer of advanced pulmonary drug delivery systems for the treatment of systemic conditions as well as lung diseases. Their hand-held AERx platform is being designed for the rapid and reproducible delivery of a wide range of pharmaceutical drugs and biotech compounds via the lung. “

Ares Management L.P. (NYSE:ARES) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $20.00 target price on the stock. According to Zacks, “Ares Management, L.P. is a global alternative asset manager. It manages four investment groups that invest in the tradable credit, direct lending, and private equity and real estate markets. The company’s Tradable Credit Group segment manages various types of investment funds, such as commingled and separately managed accounts. Its Direct Lending Group segment provides financing solutions to small-to-medium sized companies. The company’s Private Equity Group segment focuses on majority or shared-control investments primarily in under-capitalized companies. Its Real Estate Group segment invests in new developments and the repositioning of assets; and originates and invests in a range of self-originated financing opportunities for middle-market owners and operators of commercial real estate. Ares Management, L.P. is headquartered in Los Angeles. “

Argos Therapeutics (NASDAQ:ARGS) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Argos Therapeutics is a biopharmaceutical company which focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on its Arcelis (TM) technology platform. Argos Therapeutics is based in Durham, United States. “

Avino Silver and Gold Mines (NYSEMKT:ASM) was upgraded by analysts at Zacks Investment Research from a strong sell rating to a hold rating. According to Zacks, “Avino Silver & Gold Mines Ltd. is engaged in exploration and development of mineral properties. The company primarily explores for silver along with gold, copper and lead. Its properties are mainly located in British Columbia, the Yukon Territory, Mexico and Canada. Avino Silver & Gold Mines Ltd. is headquartered in Vancouver, Canada. “

Athene Holding (NYSE:ATH) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They currently have $56.00 price target on the stock. According to Zacks, “Athene Holding Ltd. is a retirement services company. Its products and services include Fixed and fixed indexed annuity products, Reinsurance services offered to third-party annuity providers and Institutional products, such as funding agreements. Athene Holding Ltd. is based in Pembroke, Bermuda. “

Axa SA (NASDAQ:AXAHY) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They currently have $32.00 price target on the stock. According to Zacks, “The AXA Group is an international group of insurance and related financial services companies. AXA’s insurance operations are diverse geographically, with activities in 50 countries, principally Western Europe, North America and the Asia/Pacific area. In the United States, AXA is represented through its 60% holding in The Equitable companies and its subsidiaries, Equitable Life, Alliance Capital management and Donaldson, Lufkin & Jenrette. “

The Middleby Corporation (NASDAQ:MIDD) was upgraded by analysts at Wellington Shields from a hold rating to an accumulate rating.

Receive News & Ratings for Advanced Accelerator Applications SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advanced Accelerator Applications SA and related companies with MarketBeat.com's FREE daily email newsletter.